CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
Vicriviroc maleatedrug
Likely dose
Vicriviroc maleate 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00686829
NCT00686829Phase 2Completed
CompareCT.gov

Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211

Merck Sharp & Dohme LLC·interventional·Posted May 30, 2008·Updated Dec 3, 2020

In Brief

A Phase 2 clinical trial evaluating Vicriviroc maleate for HIV and HIV Infections. Completed, enrolled 79 participants.

Detailed Summary

The purpose of this study is to provide open-label vicriviroc (VCV) to human immunodeficiency virus (HIV) treatment-experienced participants who successfully completed 48 weeks of treatment on Acquired Immunodeficiency Syndrome (AIDS) Clinical Trial Group (ACTG) protocol A5211 (or who responded favorably to treatment but discontinued participation due to viral tropism shifts), and participants who screened for ACTG A5211 and met all inclusion/exclusion criteria, but were unable to enroll due to protocol closure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, HIV Infections
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 30, 2008
Enrollment StartJun 30, 2005
Primary CompletionOct 21, 2010
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 18.1 years ago

Interventions

Vicriviroc maleatedrug

VCV 30 mg tablet once daily by mouth.